Page 1

MEDIA RELEASE - 18 FEBRUARY , 2021 AV SONIC HEALTHCARE LIMITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED 31 DECEMBER 2020 1 . Summary Revenue growth of 33 % to A $ 4.4 billion . • EBITDA growth of 89 % to A $ 1.3 billion . • Net profit growth of 166 % to A $ 678 million . • • • Significant revenue and earnings contribution from COVID - 19 testing , leveraging existing infrastructure . More than 18 million COVID - 19 PCR tests have been performed to date in ~ 60 Sonic laboratories globally . Global base business revenue ( ex - COVID testing ) H1 FY2021 down 1 % versus H1 FY2020 ( Constant Currency ) , significantly less impacted than in the first few months of the pandemic . • Margin accretion in both laboratory and imaging operations . • • Strong balance sheet , with gearing at record low level and A $ 1.3 billion of available liquidity ( pre - interim dividend ) . Progressive dividend policy maintained , increase of 2 cents ( 6 % ) to 36 cents for the FY2021 Interim Dividend . 2 . Commentary Sonic Healthcare today reported a statutory net profit for the half year to 31 December 2020 of A $ 678 million , on revenues of A $ 4.4 billion . Sonic's CEO , Dr Colin Goldschmidt , said : " Sonic's strong financial results for the half year reflect the millions of COVID - 19 PCR tests we have performed across our countries of operation as part of combatting the pandemic . The volumes and quality of testing we have been able to provide in such a short timeframe have only been possible through the investments we have made over many decades in our people and in infrastructure . Our Medical Leadership culture has never shone more brightly than it has through the pandemic . Our pathologists and scientists have demonstrated their expertise and initiative not only within the company but with governments and other healthcare organisations , our managers have shown tremendous flexibility and resilience in the most challenging of circumstances , and all our 37,000 staff have put their communities before themselves to ensure seamless provision of our vital services . " Our Laboratory division achieved organic revenue growth of 39 % in the half year , with very strong growth in the USA , Germany , Belgium and the UK . Without the benefit of COVID - 19 testing , our Imaging division grew revenue by 14 % , much higher than long term industry averages , an amazing outcome which included taking market share . " On the back of this strong revenue growth , the operating leverage inherent in Sonic's business was very apparent , with the level of profit growth far exceeding that of revenue . Our existing infrastructure of specimen collection facilities , courier networks , laboratories and other facilities , equipment , IT , management , staff and supply chains were all crucial to handle the increased patient volumes we have been , and continue to be , experiencing . SONIC HEALTHCARE LIMITED ABN 24 004 196 909 ⚫ LEVEL 22 , GROSVENOR PLACE ⚫ 225 GEORGE STREET ⚫ SYDNEY NSW 2000 AUSTRALIA LOCKED BAG 145⚫ NORTH RYDE ⚫ NSW 1670⚫ TELEPHONE + 61 2 9855 5444 ⚫ FACSIMILE +61 2 9878 5066